Search
Search Results
##search.searchResults.foundPlural##
-
AGING WITH THALASSEMIA AND SICKLE CELL DISEASE: A GERONTOLOGICAL MODEL OF ACCELERATED MULTIMORBIDITY AND FUNCTION-CENTERED CARE BEYOND MIDLIFE Thalassemia and Sickle Cell Diseases: Effect of Aging
580PDF: 605Suppl. Files: 78HTML: 167 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3414PDF: 997HTML: 3878 -
Guest Editor: G. Castaman AGING WITH HEMOPHILIA: THE CHALLENGE OF APPROPRIATE DRUG PRESCRIPTION Hemophilia and aging
3031PDF: 1516HTML: 327 -
TREATMENT OF CANCER IN THE OLDER AGED PERSON
1264PDF: 876HTML: 3420 -
SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML
3838PDF: 962HTML: 6884 -
HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK
1957PDF: 850HTML: 3693 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1987PDF: 1074HTML: 252 -
FROM LEGACY TO INNOVATION: PIDOTIMOD’S EXPANDING THERAPEUTIC HORIZON Pidotimod: Revisiting a Classic Immunomodulator
3094PDF: 1082HTML: 2134 -
Cardiac toxicity associated with HCV direct antiviral agents Heart in HCV DAAs therapy
1687PDF: 1033HTML: 237 -
Pidotimod in paucisymptomatic SARS-CoV2 infected patients Pidotimod in COVID-19
3294PDF: 1935HTML: 996 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2381PDF: 1873HTML: 959 -
CHRONIC MYELOGENOUS LEUKEMIA (CML) IN THE ELDERLY
2983PDF: 1181HTML: 3082 -
DEMOGRAPHICAL, VIRO-IMMUNOLOGICAL, CLINICAL AND THERAPEUTICAL CHARACTERISTICS OF HIV INFECTED PATIENTS IN A “EPIDEMIOLOGICALLY UNEXPLORED” REGION OF ITALY (CALABRIA REGION): THE CALABRHIV COHORT.
1732PDF: 875HTML: 1282Figure 1: 211Figure 2: 223Figure 3: 223 -
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA OF THE ELDERLY: REVIEW OF THE LITERATURE AND PERSPECTIVES. Hematopoietic stem cell transplatation in the elderly fo Acute Myeloid Leukemia
1824PDF: 556HTML: 359 -
Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS
993PDF: 736HTML: 266 -
Improving BNT162b2 mRNA vaccine tolerability without efficacy loss by Pidotimod supplementation Pidotimod in SARS-CoV-2 vaccination
2382PDF: 617HTML: 285 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1543PDF: 993HTML: 259 -
The INFLUENCE OF NUTRITION ON DISEASE SEVERITY AND HEALTH-RELATED QUALITY OF LIFE IN ADULTS WITH SICKLE CELL DISEASE A Prospective Longitudinal Study
2597PDF: 1012HTML: 388 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1751PDF: 1993Suppl. Files: 273HTML: 113 -
Hsa-miR-5581-3p and hsa-miR-542-3p target the F8 gene in hemophilia A without F8 mutations F8 gene is regulated by miRNAs
1208PDF: 564HTML: 394 -
HIV-ASSOCIATED VENOUS THROMBOEMBOLISM
4627PDF: 1549HTML: 8546 -
HEMATOLOGY PATIENT PROTECTION DURING THE COVID-19 PANDEMIC IN ITALY: A NATIONWIDE NURSING SURVEY Hematology patient protection during the COVID-19
1798PDF: 658HTML: 300 -
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3812PDF: 1294HTML: 5094Incidence age-standardized rates for HL across the Mediterranean basin: 253 -
EXTREMELY OLD PATIENTS HOSPITALIZED IN INTERNAL MEDICINE: WHAT ABOUT THEIR ANEMIA? Anemia in the elderly
1807PDF: 582HTML: 313 -
Measurement of erythrocyte lifespan using a CO breath test in patients with thalassemia and the impact of treatment erythrocyte lifespan in patients with thalassemia
881PDF: 612HTML: 215 -
RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES
3947PDF: 1750HTML: 11906Figures Haase: 257 -
MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY
3834PDF: 1362HTML: 2174Fig.1: 255Fig. 2: 247 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1650HTML: 688PDF: 906 -
Hypophosphatemic osteomalacia associated with tenofovir: a multidisciplinary approach is required.
1477PDF: 921HTML: 10105cover letter to the editor: 211tile page: 292 -
END-OF-LIFE CARE IN SICKLE CELL DISEASE AND TRASFUSION DEPENDEND-β-THALASSEMIA: CLINICAL, PSYCHOLOGICAL, AND ETHICAL CONSIDERATION Challenges in Supportive Care, Equity, and Compassion at End of Life
1251PDF: 881Html: 206 -
PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC Recommendation for ITP management during COVID
2920PDF: 1014HTML: 645 -







